Compare Novo Nordisk A/S (NVO) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Xcel Energy Inc — how do they compare? Novo Nordisk A/S trades at $46.46 (market cap $207.85B), while Xcel Energy Inc trades at $77.47 (market cap $48.51B). The key difference: Novo Nordisk A/S is far larger — about 4.3× Xcel Energy Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | XEL | |
|---|---|---|
Market Cap | $207.85B | $48.51B |
Sector | Health | Utilities |
52-Week High | $63.98 | $83.91 |
52-Week Low | $35.29 | $71.75 |
Enterprise Value | $222.55B | $86.82B |
Dividend Yield | 3.81% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
Xcel Energy (XEL) trades at $78.33, up 1.9% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings of $0.93 per share, beating estimates, driven by infrastructure investment recovery. Revenue for 2025 was $14.67 billion with a net income margin of 15.28%. Analysts maintain a consensus buy rating with a $93.80 price target, highlighting growth from a $60 billion capital plan through 2030.
The outlook for XEL is positive due to projected EPS growth and rising electricity demand, but risks include regulatory pushback on rate increases and high capital expenditure. The stock offers stability with a dividend yield, yet valuation remains near historical highs, requiring careful monitoring of execution against its expansive investment strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
